These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26819216)

  • 1. Orphan diseases: state of the drug discovery art.
    Volmar CH; Wahlestedt C; Brothers SP
    Wien Med Wochenschr; 2017 Jun; 167(9-10):197-204. PubMed ID: 26819216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in Inherited Retinal Disease Drug Discovery and Development: A Foundation's Perspective.
    Yerxa B
    Pharm Res; 2018 Oct; 35(11):239. PubMed ID: 30338398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia].
    Iida K; Yano T; Ikemori M; Ishida T; Nishimura N
    Yakugaku Zasshi; 2021 Jun; 141(6):877-886. PubMed ID: 33642438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Orphan drugs : New opportunities for the treatment of rare diseases].
    Beck M
    Internist (Berl); 2016 Nov; 57(11):1132-1138. PubMed ID: 27527064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug discovery and development for rare genetic disorders.
    Sun W; Zheng W; Simeonov A
    Am J Med Genet A; 2017 Sep; 173(9):2307-2322. PubMed ID: 28731526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of academic institutions in the development of drugs for rare and neglected diseases.
    Coles LD; Cloyd JC
    Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
    Vallance P; Williams P; Dollery C
    Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455
    [No Abstract]   [Full Text] [Related]  

  • 8. Orphan Drugs and Their Impact on Pharmaceutical Development.
    Attwood MM; Rask-Andersen M; Schiöth HB
    Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases.
    Swinney DC
    Clin Pharmacol Ther; 2016 Oct; 100(4):339-41. PubMed ID: 27393380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demystifying industry-academia collaboration.
    Gersdorf T; He VF; Schlesinger A; Koch G; Ehrismann D; Widmer H; von Krogh G
    Nat Rev Drug Discov; 2019 Sep; 18(10):743-744. PubMed ID: 31570836
    [No Abstract]   [Full Text] [Related]  

  • 11. Rare lung disease and orphan drug development.
    Spagnolo P; du Bois RM; Cottin V
    Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug development for orphan diseases in the context of personalized medicine.
    Brewer GJ
    Transl Res; 2009 Dec; 154(6):314-22. PubMed ID: 19931198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry.
    Mavilio F
    Gene Ther; 2017 Sep; 24(9):590-592. PubMed ID: 28485723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Birgitte Volck.
    Nat Rev Drug Discov; 2017 May; 16(6):378-379. PubMed ID: 28559559
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Modern Drug Discovery.
    Eder J; Herrling PL
    Handb Exp Pharmacol; 2016; 232():3-22. PubMed ID: 26330257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.
    Takebe T; Imai R; Ono S
    Clin Transl Sci; 2018 Nov; 11(6):597-606. PubMed ID: 29940695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Orphan drugs].
    Golocorbin Kon S; Vojinović A; Lalić-Popović M; Pavlović N; Mikov M
    Med Pregl; 2013; 66(9-10):373-8. PubMed ID: 24245445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A generalizable pre-clinical research approach for orphan disease therapy.
    Beaulieu CL; Samuels ME; Ekins S; McMaster CR; Edwards AM; Krainer AR; Hicks GG; Frey BJ; Boycott KM; Mackenzie AE
    Orphanet J Rare Dis; 2012 Jun; 7():39. PubMed ID: 22704758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategic R&D transactions in personalized drug development.
    Makino T; Lim Y; Kodama K
    Drug Discov Today; 2018 Jul; 23(7):1334-1339. PubMed ID: 29574213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.